Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$18.23
1.136.64%
At close: Jun 11, 5:00 PM EST
$18.25
1.156.73%
Pre-Market: 4:02 AM EST
Monte Rosa Therapeutics Inc Analyst Ratings
GLUENASDAQ
Monte Rosa Therapeutics Analyst Ratings and Price Targets | NASDAQ:GLUE | Benzinga
Monte Rosa Therapeutics Inc has a consensus price target of $23.13 based on the ratings of 8 analysts. The high is $37 issued by Piper Sandler on January 14, 2026. The low is $11 issued by JP Morgan on October 19, 2023. The 3 most-recent analyst ratings were released by JP Morgan, Guggenheim, and Wells Fargo on May 11, 2026, March 18, 2026, and March 18, 2026, respectively. With an average price target of $30 between JP Morgan, Guggenheim, and Wells Fargo, there's an implied 64.38% upside for Monte Rosa Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Guggenheim
Wells Fargo
Piper Sandler
Wedbush
1calculated from analyst ratings
Analyst Ratings for Monte Rosa Therapeutics
Loading calendar...
FAQ
What is the target price for Monte Rosa Therapeutics (GLUE) stock?
The latest price target for Monte Rosa Therapeutics (NASDAQ:GLUE) was reported by JP Morgan on May 11, 2026. The analyst firm set a price target for $31.00 expecting GLUE to rise to within 12 months (a possible 69.86% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Monte Rosa Therapeutics (GLUE)?
The latest analyst rating for Monte Rosa Therapeutics (NASDAQ:GLUE) was provided by JP Morgan, and Monte Rosa Therapeutics maintained their overweight rating.
When was the last upgrade for Monte Rosa Therapeutics (GLUE)?
The last upgrade for Monte Rosa Therapeutics Inc happened on December 16, 2025 when Wells Fargo raised their price target to $22. Wells Fargo previously had an equal-weight for Monte Rosa Therapeutics Inc.
When was the last downgrade for Monte Rosa Therapeutics (GLUE)?
The last downgrade for Monte Rosa Therapeutics Inc happened on December 19, 2024 when Wells Fargo changed their price target from $14 to $11 for Monte Rosa Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Monte Rosa Therapeutics (GLUE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Monte Rosa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Monte Rosa Therapeutics was filed on May 11, 2026 so you should expect the next rating to be made available sometime around May 11, 2027.
Is the Analyst Rating Monte Rosa Therapeutics (GLUE) correct?
While ratings are subjective and will change, the latest Monte Rosa Therapeutics (GLUE) rating was a maintained with a price target of $30.00 to $31.00. The current price Monte Rosa Therapeutics (GLUE) is trading at is $18.25, which is out of the analyst’s predicted range.
